17,261 trials
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants
Cystic Fibrosis
Primary: Number of Subjects With Adverse Events (Combined Part 1 and Part 2) — 7; 26; 3; 13 participants
Lymphoma
Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants
Sleep Apnea
Primary: Change in the Apnea/Hypopnea Index (AHI) Between Baseline and Week 28/Early Term. — -16.6; -31.46 events/hour — p=0.0084
Influenza
Primary: Seroconversion Rate 21 Days After the First Vaccination — 0; 82; 88.2; 94.5 percentage of participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 6 in 24-hour Weighted Mean Glucose — -43.4; -44.2 mg/dL — p=0.847
Neoplasms, Gastrointestinal Tract
Primary: Change From Start of Run-in Period in Biomarker Expression Levels at Day 0 — 0.38; 0.12; 0.15; 0.01 ratio — p=0.10
Myeloproliferative Disorders · Kidney Cancer · Leukemia
Primary: Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation — 12 participants
Head and Neck Cancer
Primary: Overall Survival — 8 months
Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Response Rate on Induction — 47.6 percentage of participants
Heart Failure · Diabetes
Primary: Effect of Thiamine Supplementation on Dyspnea — 34; 32 mm
HIV Infections · Herpes Genitalis
Primary: Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis) — 95; 110 participants — p=<0.05
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 183; 169 days
Pancreatic Cancer
Primary: Number of Patients With Progression-free Survival — 10 participants
Peripheral Arterial Disease
Primary: Length of Exercise Duration on the Treadmill Constant Work Rate Exercise Test — 15.15; 21.40 minutes — p=0.033